GENMAB A/S
GNMSFDrugs in Pipeline
6
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Epcoritamab
DLBCL
Zalutumumab
Head and Neck Neoplasms
Lenalidomide
Follicular Lymphoma (FL)
Rina-S
Non-small Cell Lung Cancer (NSCLC)
Investigator's Choice Chemotherapy
Diffuse Large B-cell Lymphoma
HuMax-CD4
Cutaneous T-Cell Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epcoritamab | Phase 3 | DLBCL | - | - |
Zalutumumab | Phase 3 | Head and Neck Neoplasms | - | - |
Lenalidomide | Phase 3 | Follicular Lymphoma (FL) | - | - |
Rina-S | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Investigator's Choice Chemotherapy | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma | - | - |
Frequently asked questions
What is in GENMAB A/S's drug pipeline?→
CatalystAlert tracks 6 drug candidates in GENMAB A/S's (GNMSF) pipeline across Phase 3, Phase 2. Its lead program is Epcoritamab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GENMAB A/S's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for GENMAB A/S (GNMSF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GNMSF biotech catalysts?→
Add GNMSF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GENMAB A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.